RE:RE:Targeting Cancer Stem Cells It reads really well, like all their pre-clinical work. The obvious question is will these findings translate into OBSERVABLE efficacy signals in patients? You have to hope it does.
There are many different ways to go after a cancer indication. One way is to target adjuvant treatment. That's where a drug is given after the primary treatment to stop recurrence. Basically you treat your patients normally in the their primary treatment. Then split the population in two and give one half SOC and the other SOC+TH1902. Success is measured by the % of patients that have their cancer come back. I don't expect they'll do that any time soon, maybe later if they ever get an approval. But this data seems to support this type of approach, mopping up any resistant CSCs left after treatment. Maybe something for a future potential partner/buyer to contemplate.
It's all good stuff, something we are use to in their preclinical work. We need the clinical evidence to unlock the value though.